BioWorld

Dec. 12, 2008

View Archived Issues

Pain Therapeutics, King Tumble On FDA's Remoxy Rejection

Shares of Pain Therapeutics Inc. plunged 21 percent Thursday after the San Mateo, Calif.-based firm said it received a complete response letter from the FDA for Remoxy, a controlled-release formulation of oxycodone. (BioWorld Today) Read More

Acusphere Hits Rock Bottom on Negative Panel Vote on Imagify

Read More

Infinity Takes Back HSP90 in Terminated AstraZeneca Deal

Read More

Vivus Hits Endpoints in First Qnexa Phase III Obesity Trial

Read More

Salix Bowel Cleansing Products Get FDA Black-Box Warning

Read More

Other News To Note

Read More

Clinic Roundup

Read More